waldenstrom macroglobulinemia

Summary

Summary: A plasma cell dyscrasia resembling leukemia with cells of lymphocytic, plasmacytic, or intermediate morphology, which secrete an IMMUNOGLOBULIN M monoclonal component. There is diffuse infiltration of bone marrow and also, in many cases, of the spleen, liver, or lymph nodes. The circulating macroglobulin produces symptoms of hyperviscosity syndrome: weakness, fatigue, bleeding disorders, and visual disturbances. Peak incidence is in the sixth and seventh decades. (Dorland, 28th ed)

Top Publications

  1. pmc Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity
    Sherine F Elsawa
    Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
    Blood 118:5540-9. 2011
  2. ncbi IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas
    N Gachard
    Laboratoires d Hématologie et d Immunologie, CHU de Limoges, Limoges and Centre National de la Recherche Scientifique, UMR CNRS 7276, Faculté de Médecine de Limoges, Universite de Limoges, Limoges, France
    Leukemia 27:183-9. 2013
  3. ncbi Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms
    Marzia Varettoni
    Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
    Blood 121:2522-8. 2013
  4. ncbi Characterization of familial Waldenstrom's macroglobulinemia
    S P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 17:488-94. 2006
  5. ncbi A new era for Waldenstrom macroglobulinemia: MYD88 L265P
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute
    Blood 121:4434-6. 2013
  6. pmc microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia
    Aldo M Roccaro
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 113:4391-402. 2009
  7. ncbi MYD88 L265P somatic mutation in Waldenström's macroglobulinemia
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, M547, 450 Brookline Ave, Boston, MA 02115, USA
    N Engl J Med 367:826-33. 2012
  8. ncbi Immunophenotypic analysis of Waldenstrom's macroglobulinemia
    J F San Miguel
    Servicio de Hematologia, Hospital Universitario de Salamanca, Spain
    Semin Oncol 30:187-95. 2003
  9. pmc Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology
    Antonio Sacco
    Dana Farber Cancer Institute, Medical Oncology, Harvard Medical School, Boston, MA, USA
    J Hematol Oncol 3:38. 2010
  10. pmc Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia
    Esteban Braggio
    Mayo Clinic, Scottsdale, Arizona 85259 5494, USA
    Cancer Res 69:3579-88. 2009

Research Grants

Detail Information

Publications221 found, 100 shown here

  1. pmc Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity
    Sherine F Elsawa
    Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
    Blood 118:5540-9. 2011
    ..Thus, together these results define a novel signaling network in the WM tumor microenvironment controlling IgM secretion and suggest CCL5 as a potential target for the treatment of this disease...
  2. ncbi IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas
    N Gachard
    Laboratoires d Hématologie et d Immunologie, CHU de Limoges, Limoges and Centre National de la Recherche Scientifique, UMR CNRS 7276, Faculté de Médecine de Limoges, Universite de Limoges, Limoges, France
    Leukemia 27:183-9. 2013
    ..WM/LPL may thus be functionally associated with constitutive nuclear factor-κB activation...
  3. ncbi Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms
    Marzia Varettoni
    Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
    Blood 121:2522-8. 2013
    ..In this latter condition, MYD88 (L265P) is associated with greater disease burden and higher risk of disease progression, and the mutation may therefore also represent a useful prognostic marker...
  4. ncbi Characterization of familial Waldenstrom's macroglobulinemia
    S P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 17:488-94. 2006
    ..Familial clustering of B-cell disorders among Waldenström's macroglobulinemia (WM) patients has been reported, though the frequency and any differences in disease manifestation for familial patients remain to be defined...
  5. ncbi A new era for Waldenstrom macroglobulinemia: MYD88 L265P
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute
    Blood 121:4434-6. 2013
    ..issue of Blood, Poulain et al demonstrate the high prevalence of the MYD88 L265P somatic mutation in patients with Waldenstrom macroglobulinemia (WM) and provide insight into its biological relevance in the growth and survival of WM.
  6. pmc microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia
    Aldo M Roccaro
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 113:4391-402. 2009
    ..These data indicate that microRNAs play a pivotal role in the biology of WM; represent important prognostic marker; and provide the basis for the development of new microRNA-based targeted therapies in WM...
  7. ncbi MYD88 L265P somatic mutation in Waldenström's macroglobulinemia
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, M547, 450 Brookline Ave, Boston, MA 02115, USA
    N Engl J Med 367:826-33. 2012
    ..Waldenström's macroglobulinemia is an incurable, IgM-secreting lymphoplasmacytic lymphoma (LPL). The underlying mutation in this disorder has not been delineated...
  8. ncbi Immunophenotypic analysis of Waldenstrom's macroglobulinemia
    J F San Miguel
    Servicio de Hematologia, Hospital Universitario de Salamanca, Spain
    Semin Oncol 30:187-95. 2003
    ..Finally, the number of mast cells was significantly higher (0.058 +/- 0.13) as compared to normal BM (0.019 +/- 0.02) (P <.01), although they were immunophenotypically normal (CD117(+)CD2(-)CD25(-))...
  9. pmc Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology
    Antonio Sacco
    Dana Farber Cancer Institute, Medical Oncology, Harvard Medical School, Boston, MA, USA
    J Hematol Oncol 3:38. 2010
    ..minimal changes; microRNA aberrations and modification in the histone acetylation status of primary Waldenstrom Macroglobulinemia tumor cells have been described...
  10. pmc Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia
    Esteban Braggio
    Mayo Clinic, Scottsdale, Arizona 85259 5494, USA
    Cancer Res 69:3579-88. 2009
    ....
  11. pmc Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia
    Irene M Ghobrial
    Dana Farber Cancer Institute, Boston, MA, USA
    Clin Cancer Res 16:1033-41. 2010
    ..Based on preclinical studies, we conducted a phase II clinical trial testing the efficacy and safety of the Akt inhibitor perifosine in patients with relapsed/refractory WM...
  12. ncbi Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
    Roger G Owen
    Leeds General Infirmary, Leeds, UK
    Semin Oncol 30:110-5. 2003
    ..Patients with clinical features attributable to IgM monoclonal gammopathy but no overt evidence of lymphoma are considered to constitute a distinct clinical group and the term "IgM-related disorders" is proposed...
  13. ncbi Lenalidomide and rituximab in Waldenstrom's macroglobulinemia
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:355-60. 2009
    ..We therefore evaluated lenalidomide and rituximab in symptomatic Waldenstrom's macroglobulinemia (WM) patients naive to either agent...
  14. ncbi Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group
    Christine I Chen
    Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 25:1570-5. 2007
    ..To evaluate the efficacy and toxicity of single-agent bortezomib in Waldenström's macroglobulinemia (WM)...
  15. pmc Thalidomide and rituximab in Waldenstrom macroglobulinemia
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, USA
    Blood 112:4452-7. 2008
    ..We therefore conducted a phase 2 study using thalidomide and rituximab in symptomatic Waldenstrom macroglobulinemia (WM) patients naive to either agent...
  16. ncbi Trisomy 4, a new chromosomal abnormality in Waldenström's macroglobulinemia: a study of 39 cases
    C Terre
    Leukemia 20:1634-6. 2006
  17. ncbi Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients
    Meghan Rourke
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Leuk Lymphoma 51:1779-92. 2010
    Many novel therapeutic agents are being tested in clinical trials for Waldenstrom macroglobulinemia (WM)...
  18. ncbi Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia
    Leukothea Ioakimidis
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Lymphoma Myeloma 9:62-6. 2009
    ..The use of CP-R might provide analogous treatment responses to more intense cyclophosphamide-based regimens while minimizing treatment-related complications in patients with WM...
  19. ncbi MYD88 L265P mutation in Waldenstrom macroglobulinemia
    Stephanie Poulain
    Department of Hematology Immunology Cytogenetic, Centre Hospitalier, Valenciennes, France
    Blood 121:4504-11. 2013
    ..A whole exome-sequencing study of Waldenstrom macroglobulinemia (WM) suggested a high frequency of MYD88 L265P mutation in WM...
  20. ncbi Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia
    Irene M Ghobrial
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Am J Hematol 85:670-4. 2010
    ..No grade 3 or 4 neuropathy occurred. The combination of weekly bortezomib and rituximab exhibited significant activity and minimal neurological toxicity in patients with untreated WM...
  21. pmc Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia
    Irene M Ghobrial
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 28:1422-8. 2010
    ..This study aimed to determine activity and safety of weekly bortezomib and rituximab in patients with relapsed/refractory Waldenström macroglobulinemia (WM)...
  22. ncbi Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease
    Alessandra Tedeschi
    Division of Hematology, Niguarda Ca Granda Hospital, Milan, Italy
    Cancer 118:434-43. 2012
    ..The authors report the final results from a multicenter, prospective study examining FCR in Waldenstrom macroglobulinemia (WM).
  23. pmc Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, M547, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 27:3830-5. 2009
    ..We examined the activity of bortezomib, dexamethasone, and rituximab (BDR) in patients with symptomatic, untreated Waldenström macroglobulinemia (WM)...
  24. ncbi Radiation therapy and combination of cladribine, cyclophosphamide, and prednisone as treatment of Bing-Neel syndrome: Case report and review of the literature
    Julio Delgado
    Department of Hematology, Hospital Universitario La Paz, Madrid, Spain
    Am J Hematol 69:127-31. 2002
    ..All similar cases reported in the literature are reviewed and the different therapeutic approaches discussed...
  25. pmc Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:824-33. 2010
    ..Autologous stem cell transplant should be considered in all eligible patients with relapsed disease...
  26. ncbi International prognostic scoring system for Waldenstrom macroglobulinemia
    Pierre Morel
    Hôpital Schaffner, Lens, France
    Blood 113:4163-70. 2009
    ..Thus, the ISSWM may provide a means to design risk-adapted studies. However, independent validation and new biologic markers may enhance its significance...
  27. pmc Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia
    Aldo M Roccaro
    Medical Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA
    Blood 115:559-69. 2010
    ..previously shown clinical activity of a mammalian target of rapamycin (mTOR) complex 1 inhibitor in Waldenstrom macroglobulinemia (WM). However, 50% of patients did not respond to therapy...
  28. ncbi How I treat Waldenström macroglobulinemia
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 114:2375-85. 2009
    ..Newer agents, such as bendamustine and everolimus, can also be considered in the treatment of WM...
  29. pmc Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 113:3673-8. 2009
    ..This study is registered at clinicaltrials.gov as NCT00020800...
  30. ncbi Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide
    Meletios Athanasios Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    J Clin Oncol 25:3344-9. 2007
    ..To improve these results, we designed a phase II study that included previously untreated symptomatic patients with WM who received a combination of dexamethasone, rituximab, and cyclophosphamide (DRC)...
  31. pmc Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia
    Irene M Ghobrial
    Dana Farber Cancer Center, Boston, MA, USA
    J Clin Oncol 28:1408-14. 2010
    ..CONCLUSION Everolimus has high single-agent activity with an overall response rate of 70% and manageable toxicity in patients with relapsed WM and offers a potential new therapeutic strategy for this patient group...
  32. ncbi Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia
    Constantine S Tam
    Department of Haematology, Peter MacCallum Cancer Centre, A Beckett Street, East Melbourne, Victoria 8006, Australia
    Clin Lymphoma Myeloma 6:136-9. 2005
    ..No cases of secondary myelodysplasia or leukemia were encountered...
  33. ncbi 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia
    Donna M Weber
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Semin Oncol 30:243-7. 2003
    ..These observations support the potential role of 2-CdA regimens as the treatment of choice for previously untreated WM...
  34. pmc Targeting NF-kappaB in Waldenstrom macroglobulinemia
    Xavier Leleu
    Medical Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA
    Blood 111:5068-77. 2008
    ..This combination led to synergistic cytotoxicity in Waldenstrom macroglobulinemia (WM) cells that was mediated through a combined reduction of the PI3K/Akt and ERK signaling pathways, ..
  35. ncbi Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Semin Oncol 30:265-9. 2003
    ..Our preliminary data indicate that this combination may be a useful salvage regimen for some patients with heavily pretreated macroglobulinemia...
  36. ncbi Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, Euroclinic Hospital, Athens, Greece
    Haematologica 90:1655-8. 2005
    ..Thus, this agent is worth studying in patients with Waldenström's macroglobulinemia (WM)...
  37. ncbi Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia
    Sophia Adamia
    Departments of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB
    Blood 112:5111-21. 2008
    ..toward aberrant splicing of the hyaluronan synthase 1 (HAS1) gene in multiple myeloma (MM) and Waldenstrom macroglobulinemia (WM), we sequenced 3616 bp in HAS1 exons and introns involved in aberrant splicing, from 17 patients...
  38. ncbi The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Gro
    C Buske
    Department of Internal Medicine III, University of Munich, Munich, Germany
    Leukemia 23:153-61. 2009
    ..0241). There was no major difference of treatment-associated toxicity between both treatment groups. These data indicate that the addition of rituximab to front-line chemotherapy improves treatment outcome in patients with LPL or WM...
  39. ncbi Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia
    Anne Sophie Moreau
    Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Blood 109:4964-72. 2007
    ..028). Our studies therefore show that enzastaurin has significant antitumor activity in WM both in vitro and in vivo, providing the framework for clinical trials to improve patient outcome in WM...
  40. ncbi Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia
    Aldo M Roccaro
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 18:6609-22. 2012
    ..activity as a single agent in hematologic malignancies, with reported responses of 30% to 70% in Waldenstrom macroglobulinemia. However, the specific mechanisms by which this class of mTOR inhibitors exerts anti-Waldenstrom ..
  41. ncbi Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study
    Irene M Ghobrial
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Cancer 101:2593-8. 2004
    The goal of the current study was to characterize the initial upsurge in immunoglobulin M (IgM) levels after treatment with rituximab in patients with Waldenstrom macroglobulinemia (WM).
  42. ncbi FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation
    Abdel Kareem Azab
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 17:4389-99. 2011
    ..In this study, we tested FGFR3 as a therapeutic target in WM and tested the effect of dovitinib on cell proliferation and apoptosis of WM cells in the context of BM microenvironment...
  43. ncbi Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia
    Xavier Leleu
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 113:626-34. 2009
    b>Waldenstrom macroglobulinemia (WM) is an incurable low-grade lymphoma characterized by bone marrow (BM) involvement of IgM secreting lymphoplasmacytic cells...
  44. ncbi Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma
    Veronique Leblond
    Département d Hématologie Hôpital Pitié Salpêtrière APHP, UPMC Universite Paris 06, GRC11 GRECHY, 75013, Paris, France
    J Clin Oncol 31:301-7. 2013
    ..No large randomized studies have yet been reported comparing any of these approaches...
  45. ncbi High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
    Charalampia Kyriakou
    North West London, NHS Trust, Watford Rd, Harrow, Middlessex, HA1 3UJ, United Kingdom
    J Clin Oncol 28:2227-32. 2010
    ..The aim of this study was to analyze the results of ASCT in patients with WM and to determine the prognostic factors that have a significant impact on outcome...
  46. ncbi High-throughput genomic analysis in Waldenström's macroglobulinemia
    Stephanie Poulain
    UF de Biologie Moléculaire, CH de Valenciennes, Valenciennes, France
    Clin Lymphoma Myeloma Leuk 11:106-8. 2011
    ..Herein, we summarize the current knowledge of WM genomic basis using these high-throughput techniques...
  47. ncbi Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
    Robert A Kyle
    Mayo Clinic, Rochester, MN, USA
    Semin Oncol 30:116-20. 2003
    ..However, the panel felt that current data are inadequate to support the use of any prognostic marker to select the timing and type of therapy, and called for studies on the application of prognostic markers in WM...
  48. ncbi Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia
    Jenny Y Sun
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Clin Lymphoma Myeloma Leuk 11:152-6. 2011
    ..These results provided a framework for examining HDAC inhibitors as monotherapy, as well as combination therapy with bortezomib in WM...
  49. ncbi Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Clin Cancer Res 13:3320-5. 2007
    ..Waldenstrom's macroglobulinemia (WM) is a B-cell disorder. Despite advances in the therapy, WM remains incurable. As such, novel therapeutic agents are needed for the treatment of WM...
  50. ncbi Are you sure this is Waldenstrom macroglobulinemia?
    Irene M Ghobrial
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Hematology Am Soc Hematol Educ Program 2012:586-94. 2012
    ..The differential diagnosis of WM includes IgM-multiple myeloma, marginal zone lymphoma, mantle cell lymphoma, and follicular lymphoma...
  51. ncbi Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions
    Roelandt F J Schop
    Department of Hematology and Internal Medicine and the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 100:2996-3001. 2002
    ..However, WM tumor cells, which appear to be diploid or near diploid, often have deletions of 6q21...
  52. ncbi Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen
    Steven P Treon
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 154:357-62. 2011
    ..Prospective studies aimed at clarifying the role of M-Rituximab therapy in WM patients are needed to confirm these findings...
  53. ncbi Guidelines on the management of Waldenström macroglobulinaemia
    S A Johnson
    Taunton and Somerset NHS Trust, Taunton, UK
    Br J Haematol 132:683-97. 2006
  54. ncbi Lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia: an evolving concept
    Pei Lin
    From the Department of Hematopathology, UTMD Anderson Cancer Center, Houston, Texas 77030, USA
    Adv Anat Pathol 12:246-55. 2005
    The concept of Waldenstrom macroglobulinemia has evolved from the original description of a clinical syndrome to its more recent designation as a distinct clinicopathologic entity, that is, lymphoplasmacytic lymphoma/Waldenstrom ..
  55. ncbi 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis
    E M Ocio
    Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain
    Br J Haematol 136:80-6. 2007
    ..Finally, the survival analysis did not show differences between the two groups of patients, probably due to the short follow up of our series...
  56. pmc Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003
    Madhav V Dhodapkar
    Section of Hematology and Yale Cancer Center, Yale University, New Haven, CT 06510, USA
    Blood 113:793-6. 2009
    The survival of patients with Waldenstrom macroglobulinemia (WM) varies enormously. The development of prognostic models in WM has been fraught by limited follow-up in current studies...
  57. ncbi Treatment of Waldenstrom's macroglobulinemia with thalidomide
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Greece
    J Clin Oncol 19:3596-601. 2001
    ..We performed a prospective phase II study to assess the activity of thalidomide in patients with Waldenstrom's macroglobulinemia (WM)...
  58. ncbi The incidence and survival of Waldenström's Macroglobulinaemia in South East England
    K J Phekoo
    Kings College Hospital, Denmark Hill, London, UK
    Leuk Res 32:55-9. 2008
    ..The relative 5 year survival for patients aged less than 70 years was 70% (95% CI: 60-81%) and for patients aged 70 and over it was 50% (95% CI: 41-60%)...
  59. ncbi 14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia
    Herve Avet-Loiseau
    Laboratory of Hematology, University Hospital, Nantes, France
    Semin Oncol 30:153-5. 2003
    ..Especially in IgM MM, the search for t(11;14) might be useful in difficult cases to discriminate with WM...
  60. ncbi Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's macroglobulinemia
    Marcel N Menke
    Schepens Retina Associates Foundation, Boston, MA, USA
    Clin Lymphoma Myeloma 9:100-3. 2009
    ..In addition, the effect of plasmapheresis on HVS-related retinopathy was tested...
  61. ncbi Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenstrom macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy
    Jia Li
    Cancer Immunology Group, Faculty of Pharmacy, University of Sydney, Sydney, Australia
    Blood 115:3580-8. 2010
    ..Proliferation tracking after stimulation confirmed their anergic state. Our studies demonstrate the incidence, NA sensitivity, and nature of clonal CTLs in WM and highlight mechanisms that cause anergy in these cells...
  62. pmc Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab
    Steven P Treon
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 118:276-81. 2011
    ..Late AITP is a newly recognized complication of alemtuzumab in this patient population. This study is registered at www.clinicaltrials.gov as NCT00142181...
  63. pmc microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia
    Aldo M Roccaro
    Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 116:1506-14. 2010
    ..These findings confirm that histone-modifying genes and HDAC activity are deregulated in WM cells, partially driven by the aberrant expression of miRNA-206 and -9* in the tumor clone...
  64. pmc High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas
    Esteban Braggio
    Mayo Clinic, Scottsdale, AZ 85259 5494, USA
    Clin Lymphoma Myeloma 9:39-42. 2009
    ..The genetic consequences of these specific abnormalities remain elusive and further studies are critical to refine the search and to precise the molecular pathways affected by these abnormalities...
  65. ncbi Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia
    Athanasios Anagnostopoulos
    Medical Oncology, Alexandra Hospital, Athens, Greece
    Biol Blood Marrow Transplant 12:845-54. 2006
    ..Allogeneic SCT carries a much higher (40%) risk of NRM and should not be considered outside the context of a clinical trial...
  66. pmc Genetics- and immune-related factors in the pathogenesis of lymphoplasmacytic lymphoma/ Waldenström's macroglobulinemia
    Sigurdur Y Kristinsson
    Department of Medicine, Division of Hematology, Karolinska University Hospital, Solna and Karolinska Institutet, Stockholm, Sweden
    Clin Lymphoma Myeloma 9:23-6. 2009
    ..Finally, based on novel insights on this topic, we discuss clinical implications and provide perspective on the relevance of these data for patient counseling and clinical follow-up...
  67. ncbi Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia
    Sant Rayn Pasricha
    Department of Diagnostic Haematology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
    J Clin Pathol 64:520-3. 2011
    ....
  68. pmc Waldenstrom macroglobulinemia with CD5+ expression presented as cryoglobulinemic glomerulonephropathy: a case report
    You Lim Kim
    Department of Internal Medicine, Eulji University College of Medicine, Seoul, Korea
    J Korean Med Sci 26:824-8. 2011
    b>Waldenstrom macroglobulinemia (WM) is a B-cell lymphoproliferative disorder associated with bone marrow involvement of lymphoplasmacytic lymphoma (LPL) and an IgM monoclonal gammopathy...
  69. ncbi Fludarabine in Waldenstrom's macroglobulinemia
    Veronique Leblond
    Hopital Pitie Salpetriere, Paris, France
    Semin Oncol 30:239-42. 2003
    ..The responses last from 32 to 41 months. The principal toxicity of fludarabine is myelosuppression. Trials of fludarabine combination therapy with drugs such as rituximab are ongoing...
  70. ncbi Developing diagnostic criteria in Waldenstrom's macroglobulinemia
    Roger G Owen
    HMDS Laboratory, The General Infirmary at Leeds, Leeds, UK
    Semin Oncol 30:196-200. 2003
    ....
  71. ncbi Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia
    Yawara Kawano
    Department of Hematology, Kumamoto University Hospital, 1 1 1 Honjo, Kumamoto 860 8556, Japan
    J Neurol Sci 297:101-4. 2010
    ..Here we report a 55-year-old female case of a POEMS syndrome associated with Waldenstrom macroglobulinemia. The patient had bed-bound polyneuropathy, splenomegaly, IgM-λ type monoclonal (M) protein, elevated ..
  72. ncbi Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood
    Jitra Kriangkum
    Department of Medicine, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
    Blood 104:2134-42. 2004
    Analysis of clonotypic immunoglobulin M (IgM) from 15 patients with Waldenstrom macroglobulinemia (WM) showed a strong preferential use of the VH3/JH4 gene families...
  73. ncbi A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia
    Irene M Ghobrial
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Clin Cancer Res 18:5043-50. 2012
    ..These findings provided the rationale for a multicenter phase II trial of oral enzastaurin in previously treated patients with WM...
  74. ncbi Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events
    Surinder S Sahota
    Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals, Southampton, United Kingdom
    Blood 100:1505-7. 2002
    ..Knowledge of the V(H) gene status can reveal their origin and clonal history. For Waldenstrom macroglobulinemia (WM), a distinct subtype of lymphoplasmacytic lymphoma, early data on limited sequences showed ..
  75. ncbi Proliferative glomerulonephritis with monoclonal IgM deposits without Waldenström's macroglobulinemia: case report and review of the literature
    Mayumi Yahata
    Departments of Nephrology, Iwate Prefectural Central Hospital Morioka, Iwate, Japan
    Clin Nephrol 77:254-60. 2012
    ..This condition may be recognized as proliferative glomerulonephritis with monoclonal IgM deposits similar to the recently recognized proliferative glomerulonephritis with monoclonal IgG deposits...
  76. ncbi Nephrotic syndrome and acute renal failure in non-Hodgkin lymphoplasmacytic lymphoma
    Natasa Colovic
    Institute of Hematology, Clinical Center of Serbia, Belgrade, Serbia
    Med Oncol 25:458-61. 2008
    ..Immunofluorescent and light microscopic studies of kidney biopsy showed signs of immunotactoid glomerulonephritis with deposits of IgG and C3. Hemodyalises and cytostatic therapy were without response and she died after 45 days...
  77. ncbi Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique
    M A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 47:1147-53. 2012
    ..Allogeneic transplant should be considered investigational and used only in the context of a clinical trial or when other chemotherapeutic options have been exhausted...
  78. ncbi Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop
    Roger G Owen
    St James s University Hospital, Leeds, UK
    Br J Haematol 160:171-6. 2013
    ..Planned sequential bone marrow assessments are encouraged in clinical trials...
  79. doi Development of EBV-associated diffuse large B-cell lymphoma in Waldenstrom macroglobulinemia and mantle cell lymphoma
    Abraham M Varghese
    Leuk Lymphoma 49:1618-9. 2008
  80. ncbi Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
    Charalampia Kyriakou
    North West London National Health Services Trust, Harrow, Middlessex, United Kingdom
    J Clin Oncol 28:4926-34. 2010
    ..Information regarding alloSCT in Waldenström macroglobulinemia (WM) is limited. This study presents the long-term outcome of a large series of patients with WM treated with alloSCT...
  81. pmc IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia
    Steven R Schuster
    Division of Hematology, Mayo Clinic Arizona, Scottsdale, AZ, USA
    Am J Hematol 85:853-5. 2010
    ..The subset of patients without lytic lesions or t(11;14) but with immunophenotypic features suggestive of MM need further study...
  82. pmc Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire
    Alice Garnier
    Service d Hématologie et de Thérapie Cellulaire, CHU Clermont Ferrand, Hopital Hotel Dieu, and Univ Clermont 1, EA3846 France Clermont Ferrand, France
    Haematologica 95:950-5. 2010
    ..Hence, new therapeutic approaches such as allogeneic stem cell transplantation should be evaluated in these patients...
  83. ncbi Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery
    Jitra Kriangkum
    Department of Oncology, Cross Cancer Institute, 11560 University Ave, Edmonton, AB, Canada T6G 1Z2
    Blood 107:2920-7. 2006
    ..These observations suggest that switch sequence analysis may identify the subset of patients with IgM MGUS who are at risk of progression to WM...
  84. ncbi Advanced waldenström's macroglobulinemia: a case of possible cure after systemic chemotherapy, splenic radiation and splenectomy
    Luigi Cavanna
    Medical Oncology and Hematology, Civic Hospital, Piacenza, Italy
    Acta Haematol 108:97-101. 2002
    ..This interesting case report, with advanced WM, alive, in good health and without signs of disease 18 years from diagnosis, is presented here and the role of splenectomy is debated...
  85. ncbi Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma
    Manfred Hensel
    Department of Internal Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Clin Lymphoma Myeloma 6:131-5. 2005
    ..Pentostatin has demonstrated significant activity as a single agent in patients with low-grade B-cell and T-cell lymphomas and is less myelosuppressive than other purine analogues...
  86. ncbi Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study
    Daniele Laszlo
    Department of Hematology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Clin Oncol 28:2233-8. 2010
    ....
  87. ncbi Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia
    Sergej Konoplev
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Clin Pathol 124:414-20. 2005
    ..CD23, usually of dim intensity, and CD11c are expressed commonly in LPL/WM. Rare CD5+ and CD10+ cases of LPL/WM also exist...
  88. ncbi Clinical features and treatment outcomes of lymphoplasmacytic lymphoma: a single center experience in Korea
    Young Woong Won
    Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam Gu, Seoul, South Korea
    Ann Hematol 89:1011-8. 2010
    ..The treatment approach was too heterogeneous to draw firm conclusions, however, and treatment recommendations in the future should utilize a uniform treatment strategy...
  89. ncbi Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia
    Umberto Vitolo
    Hematology Unit, Azienda Ospedaliera S Giovanni Battista Molinette, Turin, Italy
    Crit Rev Oncol Hematol 67:172-85. 2008
    ..As a significant progress in this field, response criteria and therapeutic recommendations were updated during the Third International Workshop on WM (7-10 October 2004, Paris, France)...
  90. ncbi Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia
    Meletios Athanasios Dimopoulos
    Department of Clinical Therapeutics, University of Athens, School of Medicine, Alexandra Hospital, Athens, Greece
    J Clin Oncol 27:120-6. 2009
    ..Finally, the panel reaffirmed its encouragement of the active enrollment of patients with WM onto innovative clinical trials whenever possible...
  91. pmc Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia
    Sigurdur Y Kristinsson
    Department of Medicine, Karolinska University Hospital Solna, SE 171 76 Stockholm, Sweden
    J Natl Cancer Inst 102:557-67. 2010
    ..We conducted, to our knowledge, the most comprehensive study to date to evaluate associations between a personal or family history of many immune-related and/or inflammatory disorders and the subsequent risk of LPL-WM...
  92. ncbi Waldenström macroglobulinaemia
    Irene M Ghobrial
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Lancet Oncol 4:679-85. 2003
    ..We also discuss current knowledge of WM and available therapies...
  93. ncbi Waldenström's macroglobulinemia-associated retinopathy
    H Nida Sen
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Building 10, Room 10N112, 9000 Rockville Pike, Bethesda, MD 20892 1857, USA
    Ophthalmology 111:535-9. 2004
    ..To report the clinical, electrophysiologic, and immunopathologic findings in a patient with progressive retinal degeneration associated with Waldenström's macroglobulinemia...
  94. ncbi Two cases of chronic lymphoproliferative disorders in psoriatic patients treated with cyclosporine: hairy cell leukemia and Waldenstrom macroglobulinemia
    Claudio Fozza
    Istituto di Ematologia, Universita di Sassari, Viale San Pietro 12, 07100 Sassari, Italy
    Eur J Dermatol 15:271-3. 2005
    ..Here we describe the occurrence of hairy cell leukemia and Waldenstrom macroglobulinemia in two psoriatic patients treated with cyclosporine A...
  95. pmc SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia
    Hai T Ngo
    Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 112:150-8. 2008
    b>Waldenstrom macroglobulinemia (WM) is characterized by widespread involvement of the bone marrow at the time of diagnosis, implying continuous homing of WM cells into the marrow...
  96. pmc Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma
    Wee J Chng
    Department of Hematology Oncology, Mayo Clinic Scottsdale, 13208 E Shea Blvd, Suite 300, Scottsdale, AZ 85259, USA
    Blood 108:2755-63. 2006
    ..Thus, IL6 and its downstream signaling may be of biologic importance in WM. Further elucidation of the role of IL-6 in WM is warranted as this may offer a potential therapeutic avenue...
  97. ncbi Proteomic analysis of waldenstrom macroglobulinemia
    Evdoxia Hatjiharissi
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Cancer Res 67:3777-84. 2007
    To better understand the molecular changes that occur in Waldenstrom macroglobulinemia (WM), we employed antibody-based protein microarrays to compare patterns of protein expression between untreated WM and normal bone marrow controls...
  98. pmc Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden
    Sigurdur Y Kristinsson
    Department of Medicine, Division of Hematology, Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden
    Blood 112:3052-6. 2008
    ..Our findings of highly increased risks of developing LPL/WM, NHL, CLL, and MGUS support the operation of shared susceptibility genes that predispose to LPL/WM and other lymphoproliferative disorders...
  99. pmc The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia
    Xavier Leleu
    Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 110:4417-26. 2007
    b>Waldenstrom macroglobulinemia (WM) is an incurable low-grade lymphoplasmacytic lymphoma...
  100. ncbi Diagnosis and management of Waldenstrom's macroglobulinemia
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, 14561, Greece
    J Clin Oncol 23:1564-77. 2005
    ..To review the diagnostic criteria, prognostic factors, response criteria, and treatment options of patients with Waldenstrom's macroglobulinemia (WM)...
  101. pmc B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia
    Sherine F Elsawa
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905
    Blood 107:2882-8. 2006
    ..Furthermore, BLyS was found to increase the viability and proliferation of malignant B cells from WM patients. Due to the role of BLyS in WM, strategies to inhibit BLyS may potentially have therapeutic efficacy in these patients...

Research Grants17

  1. NF-KB and mTOR regulation in Waldenstrom Macroglobulinemia
    Irene M Ghobrial; Fiscal Year: 2013
    ....
  2. NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES
    STEVEN TREON; Fiscal Year: 2004
    ..Analogous to our work with Muc-1, we will also attempt to identify other PCD selective targets by generating and examining mAbs specific to the plasma cell glycoform of CD138. ..
  3. Phase 3 stem cell transplant for light chain amyloidosis
    Morie A Gertz; Fiscal Year: 2011
    ..In addition, the analysis of clonal precursor B cells in the periphery and kinetics of amyloid formation of the monoclonal light chain will allow us to define and determine the mechanisms of disease progression and response to therapy. ..
  4. Regulation of the P13K/AKT pathway in Waldenstrom Macroglobulinemia
    Irene Ghobrial; Fiscal Year: 2008
    unreadable] DESCRIPTION (provided by applicant): Waldenstrom Macroglobulinemia (WM) remains incurable with a median overall survival of 5-6 years, and most patients succumb to disease progression...
  5. BLys inhibition using TACI-Fc in patients with B-bell non-Hodgkins' Lymphoma
    Stephen Ansell; Fiscal Year: 2008
    ..abstract_text> ..
  6. Clinical Activity of 17-AAG in Lymphoma
    Anas Younes; Fiscal Year: 2007
    ..In Aim 3 we will correlate the biologic effects of 17-AAG and clinical response in patients with relapsed MCL, ALCL, and HL. [unreadable] [unreadable] [unreadable]..
  7. Endotoxin-induced Uveitis Revisited
    James T Rosenbaum; Fiscal Year: 2010
    ..Future studies can buil d on these observations to test anti-inflammtory molecules induced by endotoxin as these molecules are potentially useful in the treatment of uveitis and other inflammations. ..
  8. FOUR DIMENSIONAL IMAGING OF THE IMMUNE RESPONSE IN VIVO
    James T Rosenbaum; Fiscal Year: 2010
    ..These studies should result in a fundamental improvement in the understanding of how T cells behave within a site of inflammation. ..
  9. UVEITIS GENE-EXPRESSION PROFILING
    James Rosenbaum; Fiscal Year: 2008
    ..The creation of a gene expression data base for patients with uveitis has the potential to clarify the pathogenesis of disease, establish new diagnostic tools, and provide a means for predicting prognosis. ..
  10. CHEMOTACTIC FACTORS IN ANIMAL MODELS OF UVEITIS
    James Rosenbaum; Fiscal Year: 2008
    ..We believe that these aims are novel, innovative, especially suited to the skills and achievements demonstrated by our laboratory, and highly relevant to clarifying the pathogenesis of anterior uveitis. ..
  11. Cell Sorting and Molecular Analysis for Minimal Disease Detection
    Barbara Zehentner; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  12. IMMUNOLOGY/MOLECULAR BIOLOGY TRAINING IN OPHTHALMOLOGY
    James Rosenbaum; Fiscal Year: 2007
    ..The quality of the institution, the talents of the specific faculty, the abilities of the applicant pool, and the proven success of the program areadditional strengths of this application. ..
  13. Attitudes and Beliefs and the Steps of HIV Care
    Thomas Giordano; Fiscal Year: 2008
    ..These studies will allow us to identify modifiable factors for improving outcomes, and target the Step of HIV Care where interventions should be focused to maximize impact. ..
  14. Anterior Uveal Dendritic Cells
    James Rosenbaum; Fiscal Year: 2004
    ..These studies will clarify the function of the immune system within the eye and may suggest novel therapeutic approaches in the treatment of uveitis. ..
  15. HIV, Race and Survival in the Highly Active Therapy Era
    Thomas Giordano; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  16. Targeting myeloma via dendritic cells
    Madhav Dhodapkar; Fiscal Year: 2009
    ..abstract_text> ..
  17. PI3K Pathway Inhibitors for Mantle Cell Lymphoma
    Thomas Witzig; Fiscal Year: 2006
    ....